- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Cystic fibrosis
- Meeting Date: July 2021
- Public Summary Document (PSD) July 2021 PBAC Meeting - (PDF 1304KB)
- Public Summary Document (PSD) July 2021 PBAC Meeting - (Word 200KB)
Lumacaftor + ivacaftor – July 2021
Lumacaftor + ivacaftor: Tablet containing lumacaftor 100 mg with ivacaftor 125 mg; Orkambi®
Last updated
12 November 2021